Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Grows By 134.0%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 12,400 shares, a growth of 134.0% from the December 15th total of 5,300 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 49,800 shares, the days-to-cover ratio is presently 0.2 days.

Barinthus Biotherapeutics Trading Down 8.7 %

Shares of NASDAQ:BRNS traded down $0.09 during trading on Tuesday, hitting $0.94. 1,346 shares of the stock were exchanged, compared to its average volume of 36,447. The company has a fifty day moving average price of $1.08 and a two-hundred day moving average price of $1.24. The company has a market cap of $37.81 million, a PE ratio of -0.63 and a beta of -0.81. Barinthus Biotherapeutics has a 12-month low of $0.80 and a 12-month high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.23. The business had revenue of $14.97 million during the quarter. During the same period in the previous year, the business earned ($0.37) EPS. Equities research analysts anticipate that Barinthus Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their price objective on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.